ADC Therapeutics Raises $105m To Reach Pivotal Studies

A second round of funding in just over a year is expected to allow the Lausanne, Switzerland-based company to reach the start of pivotal studies for its novel antibody-drug conjugates.

The Swiss biotech ADC Therapeutics SARL will use an additional $105m of funding it has just raised in a private placement to support the development of two antibody-drug conjugate products it has in Phase I clinical studies that are already producing initial signs of efficacy, and other early-stage pipeline products.

Although antibody-drug conjugate drugs have not attracted the sort of attention lavished on the immune-oncology sector, the new funding round...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Financing

In Brief: Soleno To Raise $200m To Boost Vykat XR Launch

 
• By 

Soleno Therapeutics will raise about $200m gross proceeds from an offering of 2.35m of its common stock to fund the commercialization of Vykat XR, which became the first drug for Prader-Willi syndrome to gain US approval on March 26.

Investors Back Nuclidium’s Next-Gen Copper-Based Radiopharmaceuticals

 

The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.

Finance Watch: Two New Venture Capital Funds Provide $600m For Biopharma

 
• By 

Private Company Edition: Catalio raised more than $400m for its fourth health care-focused VC fund, while AN Venture Partners raised $200m for Japan and beyond. In VC financings, among a dearth of mega rounds, Neuron23’s $96.5m series D is the largest round in recent weeks.

Actithera Raises $75m To Enter Competitive FAP-Targeting Radioligand Field

 

While companies such as Eli Lilly and Roche have faced setbacks to their fibroblast activation protein-targeting oncology therapies, Actithera believes its radiopharmaceuticals platform will prove more successful.

More from Business

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: Merck & Co’s Verona acquisition; venture funding plummets in Q2; how Teva is expanding innovation; Apogee’s Phase II eczema win; and a look at India’s wave of licensing.

Capricor Gets Complete Response For DMD Cell Therapy

 
• By 

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.

Bayer Bags First Global Okay For Hot Flashes Therapy

 
• By 

Lynkuet will compete with Astellas's Veozah/Veoza